A. Necchi

Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti-PD-(L)1 therapy.

BACKGROUND The phase 3, randomized, open-label LITESPARK-011 trial (NCT04586231) investigated belzutifan plus lenvatinib versus cabozantinib in participants with advanced clear-cell renal-cell carcinoma (ccRCC) following anti-PD-(L)1 therapy. At earlier analyses, belzutifan plus lenvatinib significantly improved progre...

Rare prostate cancer histologies: detection, characteristics and treatment.

Real-world overall survival improvements in metastatic urothelial carcinoma across three key therapeutic temporal periods

Background Over the past decades, treatment of metastatic urothelial carcinoma (mUC) has been transformed by three backbone therapies: platinum-based chemotherapy (PBC), immune checkpoint inhibitors (ICIs), and antibody-drug conjugates (ADCs), used alone or in combination. Evaluating temporal trends in overall survival...

Positive surgical margins after partial nephrectomy across changing surgical eras: long-term oncological results from a tertiary referral center

Impact of Age on Outcomes in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World TriNetX Analysis From the Global Society of Rare Genitourinary Tumors (GSRGT).

BACKGROUND Malignancies arising in young adults often exhibit biological and clinical behaviors distinct from those in older patients. Limited data exist on the prognostic impact of age in metastatic non-clear cell renal cell carcinoma (mnccRCC). This study compared survival outcomes by age using the large-scale TriNet...

Immunohistochemical stratification of bladder small cell carcinoma reveals two major phenotypes with distinct therapeutic biomarker profiles.

Low membranous Nectin-4 expression and preferential DLL3 and SLFN11 expression in High-NE tumours support further investigation of alternative therapeutic strategies, and SmCCB may be stratified into two IHC-defined phenotypic groups with distinctive neuroendocrine differentiation and therapeutic biomarker profiles.